MDMA, cortisol, and heightened stress in recreational ecstasy users

Behavioural Pharmacology

Volumn 25, Issue 5-6, 2014, Pages 458-472

  Parrott, Andrew C ^a,d   Montgomery, Cathy ^b   Wetherell, Mark A ^c   Downey, Luke A ^a,d   Stough, Con ^d   Scholey, Andrew B ^d  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c NORTHUMBRIA UNIVERSITY   (United Kingdom)

^d SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

3,4 methylenedioxymethamphetamine; activation; cortisol; ecstasy; homeostasis; human; performance; stress

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CORTICOTROPIN; DEXFENFLURAMINE; HYDROCORTISONE; NEUROHORMONE; RECREATIONAL DRUG; PSYCHEDELIC AGENT; STREET DRUG;

ANXIETY; ARTICLE; CIRCADIAN RHYTHM; COGNITION; COPING BEHAVIOR; DANCING; DECLARATIVE MEMORY; DEPRESSION; DYSPHORIA; ENERGY EXPENDITURE; ENVIRONMENTAL STRESS; EVENT RELATED POTENTIAL; EVOKED RESPONSE; EXECUTIVE FUNCTION; HAIR; HOSTILITY; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LABORATORY TEST; LEARNING; MEMORY; MENTAL STRESS; METABOLIC STRESS; PHOBIA; RECOGNITION; SEX DIFFERENCE; SLEEP; SOCIAL BEHAVIOR; SYSTEMATIC REVIEW; THINKING; ADDICTION; ANIMAL; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; HALLUCINOGENS; HUMANS; HYDROCORTISONE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; STREET DRUGS; STRESS, PSYCHOLOGICAL; SUBSTANCE-RELATED DISORDERS;

EID: 84906078547     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000060     Document Type: Article

References (169)

1. Badrick E, Bobak M, Britton A, Kirschbaum C, Marmot M, Kumari M (2008). The relationship between alcohol consumption and cortisol secretion in an aging cohort. J Clin Endocrinol Metabol 93:750-757.
2. Baumann MH, Gendron TM, Becketts KM, Henningfield JE, Gorelick DA, Rothman RB (1995). Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. Biol Psychiatry 38:751-755.
3. Bedi G, Hyman D, de Wit H (2010). Is ecstasy an empathogen? Effects of 3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry 68:1134-1140.
4. Benningfield MM, Cowan RL (2013). Brain serotonin function in MDMA (Ecstasy) users: Evidence for persisting neurotoxicity. Neuropsychopharmacology 38:253-255.
5. Biezonski DK, Meyer JS (2011). The nature of 3,4- methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: Evidence for and against the neurodegeneration hypothesis. Curr Neuropharmacol 9:84-90.
6. Briàre FN, Fallu JS, Janosz M, Pagani LS (2012). Prospective associations between meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms in secondary school students. J Epidemiol Community Health 66:990-994.
7. Broderick JE, Arnold D, Kudielka BM, Kirschbaum C (2004). Salivary cortisol sampling compliance: Comparison of patients and healthy volunteers. Psychoneuroendocrinology 29:636-650.
8. Burgess AP, Venables L, Jones H, Edwards R, Parrott AC (2011) Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine ('ecstasy')/ polydrug users. Psychopharmacology (Berl) 216:545-556.
9. Cannon WB (1935). Stresses and strains of homeostasis. Am J Med Sci 189:1-14.
10. Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F (2009). Molecular and cellular mechanisms of Ecstasy-induced neurotoxicity: An overview. Mol Neurobiol 39:210-271.
11. Carhart-Harris RL, Nutt DJ, Munafo MR, Wilson SJ (2009). Current and former ecstasy users report different sleep to matched controls: A web-based questionnaire study. J Psychopharmacol 23:249-257.
12. Carson DS, Bosanquet DP, Carter CS, Pournajafi-Nazarloo H, Blaszczynski A, McGregor IS (2012). Preliminary evidence for lowered basal cortisol in a naturalistic sample of methamphetamine polydrug users. Exp Clin Psychopharmacol 20:497-503.
13. Chaouloff F (2000). Serotonin, stress, and corticoids. J Psychopharmacol 14:139-151.
14. Connor TJ (2004). Methylenedioxymethamphetamine (MDMA, 'ecstasy'): A stressor on the immune system. Immunology 111:357-367.
15. Cowan RL (2007). Neuroimaging research in human MDMA users: A review. Psychopharmacology (Berl) 189:539-556.
16. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH (2001). Electrophysiological evidence of serotonergic impairment in long-Term MDMA ('ecstasy') users. Am J Psychiatry 158:1687-1692.
17. Curran V (2000). Is MDMA ('ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 42:34-41.
18. Davison D, Parrott AC (1997). Ecstasy in recreational users: Self-reported psychological and physiological effects. Hum Psychopharmacol 12:91-97.
19. De La Torre R, Farre M, Roset PN, Lopez CH, Mas M, Ortuno J, et al. (2000). Pharmacology of MDMA in humans. Ann N Y Acad Sci 914:225-237.
20. Di Iorio CR,Watkins TJ, Dietrich MS, Cao A, Blackford JU, Rogers B, et al. (2012). Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users. Arch Gen Psychiatry 69:399-409.
21. Dumont GJ, Verkes RJ (2006). A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 20:176-187.
22. Edwards S, Hucklebridge F, Clow A, Evans P (2003). Components of the diurnal cortisol cycle in relation to upper respiratory symptoms and perceived stress. Psychosom Med 65:320-327.
23. Erritizoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, Svarer C, et al. (2011). In vivo imaging of cerebral serotonin transporter and serotonin (2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') and hallucinogen users. Arch Gen Psychiatry 68:562-576.
24. Fisk JE, Montgomery C, Wareing M, Murphy PN (2005). Reasoning deficits in ecstasy (MDMA) polydrug users. Psychopharmacology (Berl) 181:550-559.
25. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ (2002). The effect of 3,4-methylenedioxymethamphetamine (MDMA,'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135:649-656.
26. Fox HC, Parrott AC, Turner JJ (2001). Ecstasy use: Cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 15:273-281.
27. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ (2002). Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ('ecstasy') polydrug users. Psychopharmacology (Berl) 162:203-214.
28. Fox HC, Jackson ED, Sinha R (2009). Elevated cortisol and learning and memory deficits in cocaine dependent individuals: Relationship to relapse outcomes. Psychoneuroendocrinology 34:1198-1207.
29. Frokjaer VG, Erritzoe D, Holst KK, Jensen PS, Rasmussen PM, Fisher PM, et al. (2013). Prefrontal serotonin transporter availability is positively associated with the cortisol awakening response. Eur Neuropsychopharmacol 23:285-294.
30. Frokjaer VG, Erritzoe D, Holst KK, Madsen KS, Fisher PM, Madsen J, et al. (2014). In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users. Int J Neuropsychopharmacol 14:1-10.
31. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, et al. (1998). Serotonergic function after (+ /-)3,4-methylene-dioxymethamphetamine ('ecstasy') in humans. Int Clin Psychopharmacol 13:1-9.
32. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, et al. (2000). Longlasting effects of 3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 47:127-136.
33. Gerra G, Bassignana S, Zaimovic A, Moi G, Bussandri M, Caccavari C, Brambilla F (2003). Hypothalamic-pituitary-Adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine ('ecstasy') use history: Correlation with dopamine receptor sensitivity. Psychiatry Res 120:115-124.
34. Goeders N (2003). The impact of stress on addiction. Eur Neuropsychopharmacol 13:435-441.
35. Gold PW, Goodwin F, Chrousos GP (1998). Clinical and biochemical manifestations of depression: Relationship to the neurobiology of stress. New Engl J Med 319:413-420.
36. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55:463-508.
37. Greer G, Tolbert R (1986). Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18:319-327.
38. Hadjiefthyvoulou F, Fisk JE, Montgomery C, Bridges N (2011). Prospective memory functioning among ecstasy/polydrug users: Evidence from the Cambridge Prospective Memory Test (CAMPROMPT). Psychopharmacology (Berl) 215:761-774.
39. Hall AP, Henry JA (2006). Acute toxic effects of ecstasy (MDMA) and related compounds: Overview of pathophysiology and clinical management. Br J Anaesth 96:678-685.
40. Halpern P, Moskovich J, Avrahami B, Bentur Y, Soffer D, Peleg K (2011). Morbidity associated with MDMA (ecstasy) abuse-A survey of emergency department admissions. Hum Exp Toxicol 30:259-266.
41. Hargreaves GA, Hunt GE, Cornish JL, McGregor IS (2007). High ambient temperature increases 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy')-induced Fos expression in a region-specific manner. Neuroscience 145:764-774.
42. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT (2002). Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 162:396-405.
43. Heesch CM, Negus BH, Keffer JH, Snyder RW II, Risser RC, Eichhorn EJ (1995). Effects of cocaine on cortisol secretion in humans. Am J Med Sci 310:61-64.
44. Heffernan TM, Jarvis H, Rodgers J, Scholey AB, Ling J (2001). Prospective memory, everyday cognitive failures, and central executive function in recreational users of ecstasy. Hum Psychopharmacol 16:607-612.
45. Hellhammer DH, Fries E, Scweisthal OW, Schlotz W, Stone AA, Hagemann D (2007). Several daily measurements are necessary to reliably assess the cortisol rise after awakening: State-And trait components. Psychoneuroendocrinology 32:80-86.
46. Herbert J, Goodyer IM, Grossman AB, Hastings MH, de Kloet ER, Lightman SL, et al. (2007). Do corticosteroids damage the brain? J Neuroendocrinol 18:393-411.
47. Huether G, Zhou D, Ryuther E (1997). Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners. J Neural Transm 104:771-794.
48. Jackson M (2006). In search of stability: Hans Selye and the biology of stress. Wellcome History 32:2-4.
49. Jansen KL (1999). Ecstasy (MDMA) dependence. Drug Alcohol Depend 53:121-124.
50. Jones KA, Callan F, Blagrove MT, Parrott AC (2008). Sleep, energy and self-rated cognition across 7 nights following recreational ecstasy/MDMA use. Sleep Hypnosis 10:16-28.
51. Kennedy DO, Little W, Scholey AB (2004). Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosom Med 66:607-613.
52. King A, Munisamy G, de Wit H, Lin S (2006). Attenuated cortisol response to alcohol in heavy social drinkers. Int J Psychophysiol 59:203-209.
53. Kirkpatrick MG, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL (2012). A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 219:109-122.
54. Kirschbaum C, Tietze A, Skoluda N, Dettenborn L (2009). Hair as a retrospective calendar of cortisol production-increased cortisol incorporation into hair in the third trimester of pregnancy. Psychoneuroendocrinology 34:32-37.
55. Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, et al. (2010). Decreased cerebral cortical serotonin transporter binding in ecstasy users: A positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 133:1779-1797.
56. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR (1992). Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 18:331-341.
57. Liechti ME, Gamma A, Vollenweider FX (2001). Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154:161-168.
58. Lovallo WR (1997). Stress and health: Biological and psychological interactions. California: Sage.
59. Lovell B, Moss M, Wetherell MA (2011). The psychosocial, endocrine and immune consequences of caring for a child with autism or ADHD. Psychoneuroendocrinology 37:534-542.
60. Lovell B, Moss MC, Wetherell MA (2012). With a little help from my friends: Psychological, endocrine and health corollaries of social support in parental caregivers of children with autism and ADHD. Res Dev Disabil 33:682-687.
61. Lupien S, de Leon M, de Santi S, Convit A, Tarshish C, Nair N, et al. (1998). Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci 1:69-73.
62. MacInnes N, Handley SL, Harding GFA (2001). Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 15:181-186.
63. Majewska M (2002). HPA axis and stimulant dependence: An enigmatic relationship. Psychoneuroendocrinology 27:5-12.
64. Malberg JE, Seiden LS (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18:5086-5094.
65. Mas M, Farre M, De La Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999). Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136-145.
66. McCann UD, Ricaurte GA (2007). Effects of 3,4- methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms. Sci World J 7:231-238.
67. McCann UD, Slate SO, Ricaurte GA (1996). Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). Drug Saf 15:107-115.
68. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998). Positron emission tomographic evidence of toxic effect of MDMA ('ecstasy') on brain serotonin neurons in human beings. Lancet 352:1433-1437.
69. McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, et al. (2008). Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent 3,4-methylenedioxymethamphetamine ('ecstasy') users: Relationship to cognitive performance. Psychopharmacology (Berl) 200:439-450.
70. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C (2004). Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl) 173:434-439.
71. McDowell DM, Kleber HD (1994). MDMA: Its history and pharmacology. Psychiatr Ann 24:127-130.
72. McEwan BS (2006). Sleep deprivation as a neurobiologic and physiologic stressor: Allostasis and allostatic load. Metabolism 55 (Suppl 2):S20-S23.
73. McGregor IS, Callaghan PD, Hunt GE (2008). From ultrasocial to antisocial: A role for oxytocin in the acute reinforcing effects and long-Term adverse consequences of drug use? Br J Pharmacol 154:358-368.
74. Mejias S, Rossignol M, Debatisse D, Streel E, Servais L, Guerit JM, et al. (2005). Event-related potentials in ecstasy (MDMA) users during a visual oddball task. Biol Psychol 69:333-352.
75. Milani R, Turner JJD, Parrott AC, Parmar R (2000). Recreational drug use and psychobiological problems, collaborative UK/Italy study (5): Ecstasy (MDMA) polydrug findings. J Psychopharmacol 14:a15.
76. Milani RM, Parrott AC, Turner JJ, Fox HC (2001). Sexual functioning self-reported by ecstasy/MDMA users, other drug users, and non-drug users. 24th Annual Meeting of the Canadian College of Neuropharmacology. Conference Abstract p.62.
77. Milani RM, Parrott AC, Turner JJ, Fox HC (2004). Gender differences in selfreported anxiety, depression and somatization among ecstasy/MDMA users, poly-drug users, alcohol/tobacco users and non-drug users. Addict Behav 29:965-971.
78. Miller GE, Chen E, Zhou ES (2007). If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary adrenocortical axis in humans. Psychol Bull 133:25-45.
79. Montgomery C, Fisk JE, Newcombe R, Murphy PN (2005). The differing effects of ecstasy/polydrug use on executive components: Shifting, inhibition, updating and access to sematic memory. Psychopharmacology (Berl) 182:262-276.
80. Montgomery C, Hatton NP, Fisk JE, Ogden RS, Jansari A (2010). Assessing the functional significance of ecstasy-related memory deficits using a virtual paradigm. Hum Psychopharmacol 25:318-325.
81. Morgan MJ, McFie L, Fleetwood LH, Robinson JA (2002). Ecstasy (MDMA): Are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology (Berl) 159:294-303.
82. Morley KC, Arnold JC, McGregor IS (2005). Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 29:648-657.
83. Murnane KS, Fantegrossi WE, Godfrey JR, Banks ML, Howell LL (2010). Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys. J Pharmacol Exp Ther 334:642-650.
84. Murnane KS, Kimmel HL, Rice KC, Howell LL (2012). The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ('ecstasy'): A concurrent microdialysis and plasma analysis study. Horm Behav 61:181-190.
85. Murphy PN, Wareing M, Fisk JE, Montgomery C (2009). Executive working memory deficits in abstinent ecstasy/MDMA users: A critical review. Neuropsychobiology 60:159-175.
86. Nemeroff CB, Vale WW (2005). The neurobiology of depression: Inroads to treatment and new drug discovery. J Clin Psychiatry 66 (suppl 7):5-13.
87. Oehen P, Traber R, Widmer V, Schnyder U (2013). A randomized, controlled pilot study of MDMA ( 3,4-methylenedioxymethamphetamine)-Assisted psychotherapy for treatment of resistant, chronic post-Traumatic stress disorder (PTSD). J Psychopharmacol 27:40-52.
88. Oei NY, Everaerd WT, Elzinga BM, van Well S, Bermond B (2006). Psychosocial stress impairs working memory at high loads: An association with cortisol levels and memory retrieval. Stress 9:133-141.
89. Ogeil RP, Rajaratnam SMW, Phillips JC, Redman JR, Broadbear JH (2011). Ecstasy use and self-reported disturbances in sleep. Hum Psychopharmacol 26:508-516.
90. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, et al. (1999). Immunomodulating properties of MDMA alone and in combination with alcohol: A pilot study. Life Sci 65:309-316.
91. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, et al. (2001). Effects of repeated doses of MDMA ('ecstasy') on cell-mediated immune response in humans. Life Sci 69:2931-2941.
92. Parrott AC (2001). Human psychopharmacology of Ecstasy (MDMA): A review of fifteen years of empirical research. Hum Psychopharmacol 16:557-577.
93. Parrott AC (2002). Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837-844.
94. Parrott AC (2004). MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: The neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50:329-335.
95. Parrott AC (2005). Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 19:71-83.
96. Parrott AC (2006). MDMA in humans: Factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 20:147-163.
97. Parrott AC (2007). The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): An evidence-based review. Psychopharmacology (Berl) 191:181-193.
98. Parrott AC (2009). Cortisol and 3,4-methylenedioxymethamphetamine: Neurohormonal aspects of bioenergetic stress in ecstasy users. Neuropsychobiology 60:148-158.
99. Parrott AC (2010). Conscious awareness versus optimistic beliefs in recreational ecstasy/MDMA users. In: Perry E, Collerton D, LeBeau F, Ashton HE, editors. New horizons in the neuroscience of consciousness. Amsterdam: John Benjamins Publishers.
100. Parrott AC (2012). MDMA and temperature: A review of the thermal effects of 'Ecstasy' in humans. Drug Alcohol Depend 121:1-9.
101. Parrott AC (2012). MDMA and 5-HT neurotoxicity: The empirical evidence for its adverse effects in humans-no need for translation. Br J Pharmacol 166:1518-1520.
102. Parrott AC (2013). Human psychobiology of MDMA or 'ecstasy': An overview of 25 years of empirical research. Hum Psychopharmacol 28:289-307.
103. Parrott AC (2013). MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'ecstasy' users. Neurosci Biobehav Rev 37:1466-1484.
104. Parrott AC (2014). MDMA is certainly damaging after 25 years of empirical research: A reply and refutation of Doblin et al. (2014). Hum Psychopharmacol 29:109-119.
105. Parrott AC (2014). The potential dangers of using MDMA for psychotherapy. J Psychoactive Drugs 46:37-43.
106. Parrott AC, Lasky J (1998). Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology (Berl) 139:261-268.
107. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K (1998). Cognitive performance in recreational users of MDMA of 'ecstasy': Evidence for memory deficits. J Psychopharmacol 12:79-83.
108. Parrott AC, Sisk E, Turner J (2000). Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend 60:105-110.
109. Parrott AC, Milani R, Parmar R, Turner JJD (2001). Ecstasy polydrug users and other recreational drug users in Britain and Italy: Psychiatric symptoms and psychobiological problems. Psychopharmacology (Berl) 159:77-82.
110. Parrott AC, Buchanan T, Scholey AB, Heffernan TM, Ling J, Rodgers J (2002). Ecstasy attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 17:309-312.
111. Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB (2006). Dancing hot on ecstasy: Physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems of recreational MDMA users. Hum Psychopharmacol 21:285-298.
112. Parrott AC, Parrott L, Evans A, Kissling C, Thome J (2007). Heavy ecstasy/MDMA use at cool house parties: Substantial cortisol release and increased body temperature. J Psychopharmacol 21:a35.
113. Parrott AC, Lock J, Conner AC, Kissling C, Thome J (2008). Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: Prospective neuroendocrine and psychobiological changes. Neuropsychobiology 57: 165-180.
114. Parrott AC, Gibbs A, Scholey AB, King R, Owens K, Swann P, et al. (2011). MDMA and methamphetamine: Some paradoxical negative and positive mood changes in an acute dose laboratory study. Psychopharmacology 215:527-536.
115. Parrott AC, Lock J, Conner AC, Kissling C, Thome J (2013). MDMA can increase cortisol by 800% in dance clubbers. J Psychopharmacol 27:113-114.
116. Parrott AC, Sands HR, Jones L, Clow A, Evans P, Downey LA, Stalder T (2014). Increased cortisol levels in hair of recent ecstasy/MDMA users. Eur Neuropsychopharmacol 24:369-374.
117. Parrott AC, Moore DG, Turner JJD, Goodwin J, Min MO, Singer LT (2014). MDMA and heightened cortisol: A neurohormonal perspective on the pregnancy outcomes of mothers who used Ecstasy during pregnancy. Hum Psychopharmacol 29:1-7.
118. Prator BC (2006). Serotonin syndrome. J Neurosci Nurs 38:102-105.
119. Ramaekers JG, Kuypers KP, Samyn N (2006). Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal. Addiction 101:1614-1621.
120. Reay JL, Hamilton C, Kennedy DO, Scholey AB (2006). MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgment processes. J Psychopharmacol 20:385-388.
121. Rendell PG, Gray TJ, Henry JD, Tolan A (2007). Prospective memory impairment in 'ecstasy' (MDMA) users. Psychopharmacology (Berl) 194:497-504.
122. Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, de Wolff FA, Booij J (2002). The acute and chronic effects of MDMA ('Ecstasy') on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 26:387-396.
123. Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ (2006). Neuroimaging findings with MDMA/ecstasy: Technical aspects, conceptual issues and future prospects. J Psychopharmacol 20:164-175.
124. Reynolds RM (2013). Glucorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis. Psychoneuroendocrinology 38:1-11.
125. Roberts CA, Fairclough S, Fisk JE, Tames FT, Montgomery C (2013). Electrophysiological indices of response inhibition in human polydrug users. J Psychopharmacol 27:779-789.
126. Roberts CA, Fairclough S, Fisk JE, Tames FT, Montgomery C (2013). ERP evidence suggests executive dysfunction in ecstasy polydrug users. Psychopharmacology (Berl) 228:375-388.
127. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott AC (2003). Patterns of drug use and the influence of gender on self reports of memory ability in ecstasy users: A web based study. J Psychopharmacol 17:379-386.
128. Rodgers J, Buchanan T, Pearson C, Parrott AC, Heffernan T, Scholey AB (2006). Differential experiences of the psychobiological sequelae of ecstasy use: Quantitative and qualitative data from an internet study. J Psychopharmacol 20:437-446.
129. Roiser JP, Sahakian BJ (2004). Relationship between ecstasy use and depression: A study controlling for poly-drug use. Psychopharmacology (Berl) 173:411-417.
130. Rosenson J, Smollin C, Sporer KA, Blanc P, Olson KR (2007). Patterns of ecstasy-Associated hyponatremia in California. Ann Emerg Med 49:164-171.
131. Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI, Green AR (2004). Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. J Psychopharmacol 18:412-416.
132. Schifano F (2000). Potential human neurotoxicity of MDMA ('ecstasy'): Subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42:25-33.
133. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R (1998). MDMA ('ecstasy') consumption in the context of polydrug abuse: A report on 150 patients. Drug Alcohol Depend 52:85-90.
134. Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH (2006). Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). J Psychopharmacol 20:456-463.
135. Scholey AB, Parrott AC, Buchanan T, Heffernan T, Ling J, Rodgers J (2004). Increased intensity of ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: A www study. Addict Behav 29:743-752.
136. Scholey A, Haskell H, Robertson B, Kennedy D, Milne A, Wetherell M (2009). Chewing gum alleviates negative mood and reduces cortisol during acute laboratory psychological stress. Physiol Behav 97:304-312.
137. Scholey AB, Owen L, Gates J, Rodgers J, Buchanan T, Ling J, et al. (2011). Hair MDMA samples are consistent with reported ecstasy use: Findings from a study investigating effects of ecstasy on mood and memory. Neuropsychobiology 63:15-21.
138. Scholtz W, Hellhammer J, Schulz P, Stone AA (2004). Perceived work overload and chronic worrying predict weekend-weekday differences in the cortisol awakening response. Psychosom Med 6:207-214.
139. Schulz P, Kirschbaum C, Pruessner JC, Hellhamer D (1998). Increased free cortisol secretion after awakening in chronically stressed individuals due to workload. Stress Med 14:91-97.
140. Selye H (1956). The stress of life. New York: McGraw Hill.
141. Singer LT, Moore DG, Fulton S, Goodwin J, Turner JJ, Min MO, Parrott AC (2012). Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicol Teratol 34:303-310.
142. Singer LT, Moore DG, Min MO, Goodwin J, Turner JJ, Fulton S, Parrott AC (2012). One-year outcomes of prenatal exposure to MDMA and other recreational drugs. Pediatrics 130:407-413.
143. Soar K, Turner JJD, Parrott AC (2001). Psychiatric disorders in recreational Ecstasy (MDMA) users: A literature review focusing upon personal predisposition factors and drug histories. Hum Psychopharmacol 16:641-646.
144. Soar K, Parrott AC, Turner JJD (2005). No more the 'love drug': Sexual behaviour impairments in ecstasy users. J Psychopharmacol 19:a25.
145. Solowij N, Hall W, Lee N (1992). Recreational MDMA use in Sydney: A profile of ecstasy users and their experiences with the drug. Br J Addict 87:1161-1172.
146. Stalder T, Steudte S, Miller R, Skoluda N, Dettenborn L, Kirschbaum C (2012). Intraindividual stability in hair cortisol concentrations. Psychoneuroendocrinology 37:602-610.
147. Strohle A, Holsboer F (2003). Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 36 (Suppl 3):S207-S214.
148. Suy K, Gijsenbergh F, Baute L (1999). Emergency medical assistance during a mass gathering. Eur J Emerg Med 6:249-254.
149. Taurah L, Chandler C, Sanders G (2014). Depression, impulsiveness, sleep and memory in past and present polydrug users of 3,4- methylenedioxymethamphetamine (MDMA, ecstasy). Psychopharmacology (Berl) 231:737-751.
150. Thayer JF, Hall M, Sollers JJ III, Fischer JE (2006). Alcohol use, urinary cortisol, and heart rate variability in apparently healthy men: Evidence for impaired inhibitory control of the HPA axis in heavy drinkers. Int J Psychophysiol 59:244-250.
151. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999). Ecstasy use in Australia: Patterns of use and associated harm. Drug Alcohol Depend 55: 105-115.
152. Turner JJD, Singer LT, Moore DG, Min MO, Goodwin J, Fulton S, Parrott AC (2014). Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: Reduced depression one year after giving birth and quitting ecstasy. J Psychopharmacol 28:55-66.
153. Van Dijken GD, Blom RE, Hene RJ, Boer WH (2013). High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol Dial Transplant 28:2277-2283.
154. Verheyden SL, Hadfield J, Calin T, Curran HV (2002). Sub-Acute effects of MDMA (3,4-methylenedioxymethamphetamine, 'ecstasy') on mood: Evidence of gender differences. Psychopharmacology 161:23-31.
155. Verheyden SL, Henry JA, Curran V (2003). Acute, sub-Acute and long-Term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol 18:507-517.
156. Verkes RJ, Gigsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M (2001). Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl) 53:196-202.
157. Villamor J, Bermejo A, Fernandez P, Tabernero M (2005). A new GC-MS method for the determination of five amphetamines in human hair. J Anal Toxicol 29:135-139.
158. Wetherell MA, Sidgreaves MC (2005). Secretory immunoglobulin a reactivity following increases in workload intensity using the Defined Intensity Stressor Simulation (DISS). Stress Health 21:99-106.
159. Wetherell MA, Carter K (2014). The Multitasking Framework: The effects of increasing workload on acute psychobiological stress reactivity. Stress Health 30:103-109.
160. Wetherell MA, Montgomery C (2014). Basal functioning of the hypothalamicpituitary-Adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users. Psychopharmacology (Berl) 231:1365-1375.
161. Wetherell MA, Hyland ME, Harris JE (2004). Secretory immunoglobulin-A reactivity to acute and cumulative acute multitasking stress: Relationships between reactivity and perceived workload. Biol Psychol 66:257-270.
162. Wetherell MA, Atherton K, Grainger J, Brosman R, Scholey AB (2012). The effects of multi-Tasking on psychological stress reactivity in recreational drug users. Hum Psychopharmacol 27:167-176.
163. White SR, Obradovic T, Imel KM, Wheaton MJ (1996). The effects of methylenedioxymethamphetamine (MDMA, 'ecstasy') on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49:455-479.
164. Wilson M (2006). In search of stability: Hans Selye and the biology of stress. Wellcome History 32:2-4.
165. Winstock AR, Griffiths P, Stewart D (2001). Drugs and the dance music scene: A survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64:9-17.
166. Wolff K, Aitchison KJ (2013). Reply to 'MDMA can increase cortisol levels by 800% in dance clubbers' Parrott et al. J Psychopharmacol 27:115-116.
167. Wolff K, Tsapakis EM, Pariante CM, Kerwin RW, Forsling ML, Aitchison KJ (2012). Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. J Psychopharmacol 26:419-428.
168. Zakzanis KK, Campbell Z (2006). Memory impairment in now abstinent MDMA users and continued users: A longitudinal follow-up. Neurology 66:740-741.
169. Zhou JF, Chen P, Zhou YH, Zhang L, Chen HH (2003). 3,4- methylenedioxymethamphetamine abuse may cause oxidative stress and potential free radical damage. Free Radic Res 37:491-497.